Methods and compositions for altering function and structure of chromatin loops and/or domains

Patent metadata

Field	Value
Publication number	US-11214800-B2
Application number	US-201615753318-A
Country	US
Kind code	B2
Filing date	Aug 18, 2016
Priority date	Aug 18, 2015
Publication date	Jan 4, 2022
Grant date	Jan 4, 2022

Abstract

Chromatin 3D structure modulating agents in the context of the present invention are intended to interfere or manipulate the function of loop anchor motifs, such as CTCF motifs. In certain example embodiments, the present invention may block formation of an loop anchor or chromatin domain or induce formation of a loop anchor or chromatin domain at a targeted genomic location. For instance, a loop anchor motif can be altered, such as by mutating (including inverting) a binding motif so as to remove such a motif, or by adding new binding motifs in new locations within a loop domain, so as to reduce the size of an existing loop, so as to modify the size of an existing loop, or combinations thereof. Alternatively, the chromatin 3D structure modulating agent may bind a target region and mask a loop anchor motif, thereby preventing a loop anchor or chromatin domain from forming. The chromatin 3D structure modulating agent may bind a target region and cause a loop anchor of chromatin domain to form.

First claim

We claim:

1. A method to modify one or more existing chromatin loops or contact domains in a target region of chromatin DNA inside the nucleus of a eukaryotic cell,
wherein the target region of chromatin DNA is being extruded by each of the two subunits of a CCCTC-binding factor (CTCF) and/or cohesin-comprising extrusion complex in opposite direction with respect to the genome and wherein the target region of chromatin DNA comprises a forward and reverse CTCF or cohesin binding motif in convergent orientation on opposite strands of the extruded chromatin DNA,
said method comprising targeting one or more catalytically inactive CRISPR-Cas systems or Cas proteins to a CTCF or cohesin binding motif or within 150,000 base pairs of a CTCF or cohesin binding motif in said target region in the nucleus of the cell, wherein the catalytically inactive CRISPR-Cas systems or Cas proteins bind to a target site in the target region and are not capable of recruiting any additional biological or enzymatic activity to the target site, to thereby prevent the extrusion of at least one chromatin strand through the extrusion complex.

2. The method of claim 1 , wherein said catalytically inactive CRISPR-Cas systems or Cas proteins are targeted to a location between the forward and reverse CTCF or cohesin binding motifs at an existing loop or contact domain boundary.

3. The method of claim 2 , wherein said catalytically inactive CRISPR-Cas systems or Cas proteins are targeted to a location within 1000 base pairs following an existing forward CTCF or cohesin binding motif.

4. The method of claim 1 , wherein the CTCF or cohesin binding motif is the CTCF motif.

5. The method according to claim 1 , wherein said method further comprises the step of performing in situ Hi-C on said cell prior to or following said targeting, thereby generating an in situ Hi-C library, wherein in situ Hi-C comprises performing Hi-C in intact nuclei, and wherein said in situ Hi-C method identifies target chromatin loop modification sites or monitors the result of chromatin loop or contact domain modification in the target region.

6. The method of claim 5 , further comprising detecting changes in gene expression and/or changes in cell phenotype after said targeting.

7. The method of claim 5 , further comprising hybridizing probes specific to ligation junctions in the target region and isolating the hybridized probes.

8. The method of claim 5 , wherein said in situ Hi-C comprises the steps of:
a. generating a 3D contact map of the genome of said cell; and
b. identifying a target modification site from the 3D contact map, wherein the target modification site comprises either an existing loop or contact domain or a modified loop or contact domain.

9. The method of claim 8 , wherein said method further comprises the steps of:
c. generating a set of vectors wherein each vector encodes one or more chromatin loop perturbations, wherein expression of one or more vectors in the set of vectors results in removal of one or more existing chromatin loops or domains, introduction of one or more new chromatin loops or domains, or modification of one or more existing loops or domains at one of the identified target modification sites;
d. delivering each vector in the set of vectors to a different cell or cell population to determine an impact of the introduced chromatin loop perturbations on cell function; and
e. identifying the one or more vectors in the set of vectors that introduce the one or more chromatin perturbations.

10. The method of claim 1 , wherein targeting the one or more catalytically inactive CRISPR-Cas systems or Cas proteins to the nucleus of a cell comprises:
i. delivering one or more vectors encoding the one or more catalytically inactive CRISPR-Cas systems or Cas proteins; or
ii. delivering a cell-permeable reagent comprising the one or more catalytically inactive CRISPR-Cas systems or Cas proteins.

11. The method of claim 10 , wherein the one or more vectors are delivered in vivo.

12. The method of claim 10 , wherein the one or more catalytically inactive CRISPR-Cas systems or Cas proteins are under the inducible control of a vector promoter.

13. The method of claim 12 , wherein the vector promoter is a tissue-specific promoter or a promoter that is ubiquitously expressed.

14. The method of claim 10 , wherein the one or more vectors encoding the one or more catalytically inactive CRISPR-Cas systems or Cas proteins comprise a viral vector.

15. The method of claim 14 , wherein the viral vector is selected from the group consisting of lentiviral, adenoviral, adeno-associated viral, and herpes simplex virus vectors.

16. The method of claim 10 , wherein said cell-permeable reagent comprises a pyrrole-imidazole polyamide.

17. The method of claim 1 , wherein the one or more catalytically inactive CRISPR-Cas systems or Cas proteins target one or more existing CTCF or cohesin binding motifs.

18. The method of claim 1 , wherein said target region comprises genes the expression of which is to be modified, and wherein modification of the existing chromatin loop or contact domain alters expression of one or more of said genes.

19. The method of claim 18 , wherein one or more of the genes is associated with a disease.

20. The method of claim 19 , wherein the one or more of the genes is an oncogene or tumor suppressor gene.

21. The method of claim 20 , wherein a target region associated with aberrant expression of an oncogene is targeted, whereby expression of the oncogene is repressed; or wherein a target region associated with aberrant expression of a tumor suppressor is targeted, whereby expression of the tumor suppressor is activated.

22. The method of claim 19 , wherein the disease is a genetic disease associated with genomic imprinting, whereby an imprinted gene is unsilenced or a gene is silenced by establishing imprinting.

23. The method of claim 1 , wherein the target region comprises a virus integration site of an infectious virus, and/or
wherein the target region is associated with improved yields, disease resistance, drought resistance or salt tolerance in plant or animals.

24. The method of claim 23 , wherein the virus is a retrovirus, an adenovirus, an adeno-associated virus (AAV), a lentivirus or a herpesvirus.

25. The method of claim 1 , wherein the cell is a mammalian cell, or wherein the cell is a plant cell.

26. The method of claim 1 , wherein the extrusion complex comprises one or more members selected from the group consisting of CTCF, SA1/2, Smc3, Smc1, cohesin and Rad21.

27. The method of claim 1 , wherein two or more catalytically inactive CRISPR-Cas systems or Cas proteins are targeted to a 5 kb region containing a CTCF or cohesin binding motif, wherein the CTCF or cohesin binding motif is targeted.

28. The method of claim 27 , wherein 2-7 catalytically inactive CRISPR-Cas systems or Cas proteins are targeted to the region.

29. The method of claim 28 , wherein the catalytically inactive CRISPR-Cas systems or Cas proteins are targeted to sequences 500-1000 base pairs apart in the region and wherein the sequences targeted alternate between sequences on opposite strands in the chromatin DNA.

30. The method of claim 1 , wherein two or more catalytically inactive CRISPR-Cas systems or Cas proteins are targeted to a 5 kb region in between two CTCF or coh

Assignees

• Broad Inst Inc
• Baylor College Medicine

Inventors

• Lieberman Aiden Erez
• Lander Eric S
• Rao Suhas
• Huang Su-Chen
• Sanborn Adrian L
• Durand Neva C
• Huntley Miriam
• Jewett Andrew

Classifications

• C07K14/47 Primary

  from mammals · CPC title

• C07K14/4702

  Regulators; Modulating activity · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title